论文部分内容阅读
宫颈癌是最常见的女性生殖道恶性肿瘤之一,是导致妇女死亡的第二大癌症,随着宫颈癌筛查的开展,宫颈癌的发病率及死亡率可明显下降。初善仪(TruScreen)是一种新型的宫颈病变筛查方法,它具有与病理学诊断的一致性好、敏感性特异性较高、简单无创、易携带、客观性和实时性等特点,还可以联合其它筛查方法[宫颈涂片、新柏式薄层液基细胞学技术(ThinPrep liquid-based cytology test,TCT)、液基细胞薄层涂片(liquid-based cytology test,LCT)、人乳头状瘤病毒检测(human papilloma virus test,HPV-test)等提高宫颈疾病的检出率,在宫颈癌及癌前病变筛查及预后判断具有重大的临床应用价值。
Cervical cancer is one of the most common malignant tumors of the female genital tract and the second leading cause of death among women. With the development of cervical cancer screening, the incidence and mortality of cervical cancer can be significantly reduced. TruScreen is a new screening method for cervical lesions, which has the characteristics of good consistency with pathological diagnosis, high sensitivity, simple non-invasive, easy to carry, objectivity and real-time Other screening methods may be used [Cervical smear, ThinPrep liquid-based cytology test (TCT), liquid-based cytology test (LCT), human Cervical papilloma virus test (HPV-test) and so improve the detection rate of cervical disease in cervical cancer and precancerous lesions screening and prognosis of great clinical value.